IDiyas

For the Inventor, By the Inventor

Schlieren, Switzerland

Neurimmune Holding Ag


USPTO Granted Patents = 16



Trademarks = 11

Forward Citations = 16

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Jan Grimm (16 out of 38 patents)

silverMedal Fabio Montrasio (5 out of 10 patents)

bronzeMedal Marcel Maier (4 out of 7 patents)

4.  Fabrice Heitz (4 out of 4 patents)

5.  Maria Grazia Barenco Montrasio (3 out of 6 patents)

6.  Roger Nitsch (3 out of 28 patents)

7.  Christoph Hock (3 out of 20 patents)

8.  Tobias Welt (3 out of 3 patents)

9.  Aubin Michalon (3 out of 3 patents)

10.  Feng Chen (3 out of 7 patents)

11.  Ioana Combaluzier (3 out of 3 patents)

12.  Benoit Combaluzier (3 out of 3 patents)

13.  Ivan Jelcic (3 out of 3 patents)

14.  Roland Martin (3 out of 11 patents)

15.  Jordan Mcafoose (2 out of 2 patents)


16 patents:

1. 12234281 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2025-02-25),
2. 11608372 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2023-03-21),
3. 11401325 - Human-derived anti-huntingtin (HTT) antibodies and uses thereof (2022-08-02),
4. 11352441 - Human anti-SOD1 antibodies (2022-06-07),
5. 11180545 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2021-11-23),
6. 10961322 - Human-derived anti-dipeptide repeats (DPRs) antibody (2021-03-30),
7. 10882902 - Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof (2021-01-05),
8. 10544213 - Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance (2020-01-28),
9. 10450365 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2019-10-22),
10. 10392447 - Human-derived anti-dipeptide repeats (DPRs) antibody (2019-08-27),
11. 10344097 - Human anti-SOD1 antibodies (2019-07-09),
12. 10344080 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2019-07-09),
13. 10072074 - Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof (2018-09-11),
14. 9771413 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2017-09-26),
15. 9475866 - Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof (2016-10-25),
Neurimmune Holding AG is a biopharmaceutical company specializing in the discovery and development of human antibodies for the treatment of neurodegenerative diseases. The company focuses on translating its proprietary technology platform into therapeutics that address the underlying causes of these diseases, with a particular emphasis on Alzheimer's disease. Neurimmune's innovative approach has the potential to revolutionize the treatment of neurodegenerative conditions, offering new hope to patients and their families.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

16 Patents

#9 in Schlieren

#732 in Switzerland

#36,634 in the World

...
Schlieren, Switzerland

Neurimmune Holding Ag

Forward Citations = 16

27 inventors:

goldMedal Jan Grimm (16 out of 38 patents)

silverMedal Fabio Montrasio (5 out of 10 patents)

bronzeMedal Marcel Maier (4 out of 7 patents)

4.  Fabrice Heitz (4 out of 4 patents)

5.  Maria Grazia Barenco Montrasio (3 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…